News
Novartis' oral BTK drug moves the needle in CINDU
Novartis is set to expand the label for its oral BTK inhibitor Rhapsido, keeping the drug on course to become one of its biggest-ever brands.
R&D
Changing Faces: Board of Directors, January 2026
January was a relatively quiet month for Board news, but there were some notable moves here and there.
News
NHS study will pick apart mental illness with data science
Volunteers with schizophrenia, bipolar, and depression will take part in an NHS study that will use genetic and health data to find new therapies.
R&D
On JPM2026 and healthcare investment today, with Jonah Comst...
Editor-in-chief Jonah Comstock sat down with pharmaphorum web editor Nicole Raleigh to discuss JPM2026.
News
Compass points to strong psilocybin data in depression
Armed with new data, Compass wants to talk to the FDA about filing its psilocybin therapy COMP360 for approval in treatment-resistant depression.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
